Rentschler Biopharma is ceasing its cell and gene therapy operations, notably at its UK site, to focus on biologics. The company noted that the cell and gene therapy market’s growth has been slower than expected and didn’t meet the firm’s expectations. Recently, the firm has made significant investments to upgrade its capabilities and infrastructure, enabling it to concentrate on biopharmaceuticals.
Deepseek’s Security Risk Is A Critical Reminder For Healthcare CIOs
DeepSeek, a Chinese AI startup, sparked concern after security vulnerabilities were uncovered in their technology, exposing sensitive data from a publicly accessible database. The findings
